PALB2 and non-melanoma skin carcinoma: In summary, we identify that the BRCAness phenotype could be a pathogenic and targetable feature in subset of non-melanoma skin cancers and that PALB2 altered cells display increased sensitivity to BETi which may be further potentiated with combination of PARPi, supporting similar findings reported in other human cancers.